Not a good buy right now for an impatient buyer: the setup is late in a short-term upswing (near resistance) while fundamentals/Street sentiment are weakening.
Near-term risk is skewed to downside into earnings (2026-02-12 pre-market) given recent revenue/EPS declines and multiple recent downgrades.
Hedge funds have been adding (supportive), but the 1-month pattern-based expectation is negative (-4.48%), so the risk/reward for an immediate entry is unattractive.
Trend/Momentum: MACD histogram is positive and expanding (bullish momentum), but RSI(6)=68 is getting stretched (closer to overbought than “fresh entry”).
Structure: Moving averages are converging (no strong established trend; easier to get chopped).
Levels: Price 87.42 is pressing resistance (R1 87.659; next R2 89.172). Support is at Pivot 85.211 then S1 82.762.
Tactical read: Upside from here is limited until a clean break above ~87.66–89.17; failure there raises odds of a pullback toward ~85 and potentially ~82.8.
Quant/pattern note: Similar-pattern model implies ~-0.07% next week and ~-4.48% next month, which argues against chasing strength today.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Call-heavy positioning (OI PCR 0.79 and especially volume PCR 0.07) suggests bullish/hedged-up sentiment rather than fear.
Volatility: IV30 at 65.29 vs historical vol 34.33; IV percentile 91.63 (options are expensive, implying elevated event/earnings premium).
Activity: Volume vs 30-day average is elevated (14.02x), though absolute contract count is still modest (today’s volume 499). This looks like concentrated interest rather than broad participation.
Takeaway: Options market is leaning bullish but pricing in big moves; that typically reduces the attractiveness of “buying right now” ahead of earnings.
Technical Summary
Sell
6
Buy
6
Positive Catalysts
Hedge funds are buying (reported +599.85% QoQ in buying amount), which can provide support.
Technical momentum is currently positive (MACD expanding), and price is near a breakout area (above ~87.66 could trigger follow-through).
Earnings on 2026-02-12 (pre-market) can be a catalyst if guidance/Heydude trends surprise positively.
No negative news flow in the last week (no new headline pressure).
Neutral/Negative Catalysts
with RSI(
elevated, increasing pullback risk.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $996.3M, down -6.20% YoY (top-line contraction).
Net income: $145.8M, down -27.02% YoY (profitability hit).
EPS: 2.70, down -19.64% YoY.
Gross margin: 58.52%, down -1.86% YoY (margin pressure).
Growth read: This is not a “re-accelerating” quarter; it supports the view that CROX needs clearer stabilization before it’s an attractive chase-buy.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: ratings skewed weaker vs prior months.
2026-01-22 KeyBanc: Downgraded to Sector Weight (from Overweight), citing challenged U.S. demand, wholesale caution, tariff headwinds, and Heydude pressure; expects limited near-term catalysts.
2026-01-07 Baird: Downgraded to Neutral (from Outperform), maintained $100 PT.
2026-01-08 BWG Global: Upgraded to Mixed (from Negative) based on channel checks (a partial offset, but not an outright bullish stance).
2025-11-11 Seaport: Maintained Neutral; sees near-term initiatives weighing on results but better long-term positioning.
Wall Street pros/cons view: Pros = potential long-term brand strategy improvements and some supportive channel checks; Cons = limited near-term catalysts, pressured demand/wholesale environment, and Heydude cleanup/tariff uncertainty. Overall: cautious/neutral-to-negative near term.
Wall Street analysts forecast CROX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CROX is 90.38 USD with a low forecast of 75 USD and a high forecast of 112 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast CROX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CROX is 90.38 USD with a low forecast of 75 USD and a high forecast of 112 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 84.490
Low
75
Averages
90.38
High
112
Current: 84.490
Low
75
Averages
90.38
High
112
KeyBanc
Ashley Owens
Overweight -> Sector Weight
downgrade
AI Analysis
2026-01-22
Reason
KeyBanc
Ashley Owens
Price Target
AI Analysis
2026-01-22
downgrade
Overweight -> Sector Weight
Reason
KeyBanc analyst Ashley Owens downgraded Crocs to Sector Weight from Overweight without a price target. The company's U.S. demand remains challenged, the analyst tells investors in a research note. The firm sees limited visibility for Crocs given ongoing wholesale caution, tariff headwinds, and continued pressure at Heydude as the channel cleanup continues. KeyBanc believes the stock has limited catalysts near-term and prefer to remain on the sidelines until the company's compares get easier in the second half of 2026.
BWG Global
Negative
to
Mixed
upgrade
2026-01-08
Reason
BWG Global
Price Target
2026-01-08
upgrade
Negative
to
Mixed
Reason
BWG Global upgraded its view of Crocs to Mixed from Negative, citing checks with buyers, distributors and managers from China and the U.S.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CROX
